Trial · NCT01404312
Results by group54
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 54
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Incidence of First Diagnosis of Active Tuberculosis, Death Related to Tuberculosis, or Death From Unknown Cause | RPT Plus INH Regimen (Arm A) | 0.6506 | 95.1% Confidence Interval 0.4242 to 0.8770 | Events per 100 person-years | |
| Incidence of First Diagnosis of Active Tuberculosis, Death Related to Tuberculosis, or Death From Unknown Cause | INH Regimen (Arm B) | 0.6736 | 95.1% Confidence Interval 0.4428 to 0.9045 | Events per 100 person-years | |
| Number of Participants With Occurrence of One or More Serious Adverse Events (SAEs) Versus no SAEs | RPT Plus INH Regimen (Arm A) | No SAE occurred | 1405 | Participants | |
| Number of Participants With Occurrence of One or More Serious Adverse Events (SAEs) Versus no SAEs | INH Regimen (Arm B) | No SAE occurred | 1390 | Participants | |
| Number of Participants With Occurrence of One or More Serious Adverse Events (SAEs) Versus no SAEs | RPT Plus INH Regimen (Arm A) | At least one SAE occurred | 83 | Participants | |
| Number of Participants With Occurrence of One or More Serious Adverse Events (SAEs) Versus no SAEs | INH Regimen (Arm B) | At least one SAE occurred | 108 | Participants | |
| Number of Participants With a Targeted Adverse Event | RPT Plus INH Regimen (Arm A) | No Targeted Safety Event | 1445 | Participants | |
| Number of Participants With a Targeted Adverse Event | INH Regimen (Arm B) | No Targeted Safety Event | 1446 | Participants | |
| Number of Participants With a Targeted Adverse Event | RPT Plus INH Regimen (Arm A) | Occurrence of Targeted Safety Event | 43 | Participants | |
| Number of Participants With a Targeted Adverse Event | INH Regimen (Arm B) | Occurrence of Targeted Safety Event | 52 | Participants | |
| Number of Participants in Each Category of Ordered Categorical Variable Indicating Most Stringent Level of Study Drug Management Due to Toxicity That Was Required Over the Treatment Period | RPT Plus INH Regimen (Arm A) | Premature permanent treatment discontinuation | 16 | Participants | |
| Number of Participants in Each Category of Ordered Categorical Variable Indicating Most Stringent Level of Study Drug Management Due to Toxicity That Was Required Over the Treatment Period | INH Regimen (Arm B) | Premature permanent treatment discontinuation | 25 | Participants | |
| Number of Participants in Each Category of Ordered Categorical Variable Indicating Most Stringent Level of Study Drug Management Due to Toxicity That Was Required Over the Treatment Period | RPT Plus INH Regimen (Arm A) | Treatment held for more than 7 days | 11 | Participants | |
| Number of Participants in Each Category of Ordered Categorical Variable Indicating Most Stringent Level of Study Drug Management Due to Toxicity That Was Required Over the Treatment Period | INH Regimen (Arm B) | Treatment held for more than 7 days | 31 | Participants | |
| Number of Participants in Each Category of Ordered Categorical Variable Indicating Most Stringent Level of Study Drug Management Due to Toxicity That Was Required Over the Treatment Period | RPT Plus INH Regimen (Arm A) | None of the above | 1461 | Participants | |
| Number of Participants in Each Category of Ordered Categorical Variable Indicating Most Stringent Level of Study Drug Management Due to Toxicity That Was Required Over the Treatment Period | INH Regimen (Arm B) | None of the above | 1442 | Participants | |
| Cumulative Incidence of Death From Any Cause | RPT Plus INH Regimen (Arm A) | 1 year post-entry | 0.35 | events per 100 participants | |
| Cumulative Incidence of Death From Any Cause | INH Regimen (Arm B) | 1 year post-entry | 0.63 | events per 100 participants | |
| Cumulative Incidence of Death From Any Cause | RPT Plus INH Regimen (Arm A) | 2 years post-entry | 0.49 | events per 100 participants | |
| Cumulative Incidence of Death From Any Cause | INH Regimen (Arm B) | 2 years post-entry | 1.15 | events per 100 participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01404312/results